Pfizer Weighs Options For Future Of Established Products Business Unit As Revenues Show Strong Trends: Emerging Markets Earnings Roundup (Part 3)
This article was originally published in PharmAsia News
Executive Summary
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Perhaps the most interesting Q call of all was Pfizer Inc., which discussed in more detail whether it plans to spin out its emerging markets unit.